RH5 antigenic landscape shapes vaccine and antibody development.

IF 13.9 1区医学 Q1 PHARMACOLOGY & PHARMACY

Trends in pharmacological sciences Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI:10.1016/j.tips.2024.10.008

Palak N Patel, Niraj H Tolia

引用次数: 0

Abstract

The essential interaction between Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) and basigin makes RH5 a prime target for broadly neutralizing antibodies. A recent study by Barrett et al. mapped the RH5 antigenic landscape from RH5.1/AS01_B vaccinees and identified a potent public antibody clonotype, advancing malaria vaccine and prophylactic antibody development.

查看原文本刊更多论文

RH5 抗原结构影响疫苗和抗体的开发。

恶性疟原虫网状细胞结合蛋白同源物 5（RH5）与碱性蛋白之间的重要相互作用使 RH5 成为广谱中和抗体的主要靶标。Barrett 等人最近的一项研究绘制了来自 RH5.1/AS01B 疫苗接种者的 RH5 抗原图谱，并确定了一种强效公共抗体克隆型，从而推动了疟疾疫苗和预防性抗体的开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in pharmacological sciences 医学-药学

CiteScore

23.90

自引率

0.70%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Trends in Pharmacological Sciences (TIPS) is a monthly peer-reviewed reviews journal that focuses on a wide range of topics in pharmacology, pharmacy, pharmaceutics, and toxicology. Launched in 1979, TIPS publishes concise articles discussing the latest advancements in pharmacology and therapeutics research. The journal encourages submissions that align with its core themes while also being open to articles on the biopharma regulatory landscape, science policy and regulation, and bioethics. Each issue of TIPS provides a platform for experts to share their insights and perspectives on the most exciting developments in the field. Through rigorous peer review, the journal ensures the quality and reliability of published articles. Authors are invited to contribute articles that contribute to the understanding of pharmacology and its applications in various domains. Whether it's exploring innovative drug therapies or discussing the ethical considerations of pharmaceutical research, TIPS provides a valuable resource for researchers, practitioners, and policymakers in the pharmacological sciences.